2024-512578-83-00已完成1 期
A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participants
Structure Therapeutics Inc., Structure Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2024年6月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
Eric Meltzer
Scientific
Structure Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Healthy Participantssickle cell disease10038158sickle cell anemiaNL-OMON53865Global Blood Therapeutics, Inc.9
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C-ASTX029 in Healthy Volunteersadvanced solid tumorssolid tumorsNL-OMON51576Astex Pharmaceuticals, Inc.8
撤回
1 期
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesAdvanced Solid NeoplasmsLymphoma NeoplasmsNCT03338881Calithera Biosciences, Inc
已完成
不适用
A Phase 1 Trial to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C ASTX660 in Healthy Volunteerssolid tumors, lymphomaadvanced solid tumors10024324lymphomaNL-OMON49455Astex Pharmaceuticals, Inc.8
进行中（未招募）
1 期
OP-724-001 studyHealthy volunteersJPRN-jRCT2031230432Yuushi Haruyama6